Why the study?
Does percutaneous coronary intervention (PCI) improve symptoms and quality of life in patients with stable angina who have objective evidence of ischemia?
Does percutaneous coronary intervention (PCI) improve symptoms and quality of life in patients with stable angina who have objective evidence of ischemia?
Answers are grounded in this paper and cite their sources.
This editorial highlights the ORBITA-2 trial, which provides the first double-blind, placebo-controlled evidence that PCI effectively reduces angina symptoms in patients with stable angina and objective ischemia.
The primary aim of treating patients with stable angina is to decrease symptoms and improve quality of life. Percutaneous coronary intervention (PCI), a treatment for patients with angina, does not reduce the risk of death from any cause, death from cardiac causes, or myocardial infarction.1 In this issue of the Journal, Rajkumar and colleagues2 report on the results of the ORBITA-2 trial, which is the first double-blind, randomized, placebo-controlled trial to show that PCI is an effective antianginal treatment in patients with stable angina who have objective evidence of ischemia. ORBITA-2 was an elegant and rigorous trial that was designed . . .
No takes yet. Share an insight, caveat, or question.
Harvey D. White (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: